Evaluation of the ISL1 gene in the pathogenesis of bladder exstrophy in a Swedish cohort.
Samara ArkaniJia CaoJohanna LundinDaniel NilssonThomas KällmanGillian BarkerGundela HolmdahlChristina Clementsson KockumHans MatssonAgneta NordenskjöldPublished in: Human genome variation (2018)
Bladder exstrophy is a congenital closure defect of the urinary bladder with a profound effect on morbidity. Although the malformation is usually sporadic, a genetic background is supported by an increased recurrence risk in relatives, higher concordance rates in monozygotic twins and several associated chromosomal aberrations. Recently, the ISL1 gene was presented as a candidate gene for bladder exstrophy and epispadias complex (BEEC) development in two different studies. In our study, we screened for genetic variants in the ISL1 gene in DNA from 125 Swedish patients using Sanger sequencing and array-CGH analysis. In addition, we evaluated ISL1 expression in RNA of human bladder during embryonic and fetal weeks 5-10 relative to that in lung tissue (week 9). In total, 21 single-nucleotide variants were identified, including a potentially novel missense variant, c.137C>G p.(Ala46Gly), substituting a conserved amino acid. This variant was inherited from an unaffected mother. No structural variants were identified. RNA sequencing revealed ISL1 mRNA expression during the critical time frame of human bladder development. In conclusion, we did not detect any known or likely pathogenic variants in the ISL1 gene in 125 Swedish BEEC patients, indicating that variation in the ISL1 gene is not a common genetic mechanism of BEEC development in the Swedish population.
Keyphrases
- copy number
- genome wide
- spinal cord injury
- end stage renal disease
- endothelial cells
- genome wide identification
- dna methylation
- ejection fraction
- single cell
- newly diagnosed
- prognostic factors
- randomized controlled trial
- poor prognosis
- peritoneal dialysis
- amino acid
- high resolution
- transcription factor
- long non coding rna
- high throughput
- single molecule
- clinical trial
- late onset
- preterm birth
- gestational age
- induced pluripotent stem cells
- double blind